Jonathan Barratt, MD, consultant nephrologist and professor of renal medicine, University of Leicester and John Walls Renal Unit, Leicester, provides a comprehensive overview of IgA nephropathy. Professor Barratt also discusses updates on new treatments for patients with IgA nephropathy.
Heather N. Reich, MD, CM, PhD, FRCPC, Oreopoulos-Baxter Division Director of Nephrology, University of Toronto, discusses translating new clinical trials in IgA nephropathy, a kidney disease. Dr Reich…
Sean Converse was diagnosed with IgA nephropathy in late 2022 following an acute upper respiratory illness. Sean discusses challenges and his experience with IgA nephropathy.
Clarissa Tio, MD, a nephrologist at the University of Mississippi, moderates a discussion between Ariana Barton, a patient living with IgA nephropathy and a patient advocate, Joshua Samuels,…
Dana Rizk, MD, professor of medicine at the University of Alabama at Birmingham, discusses the approval of Fabhalta (iptacopan) for adults with IgA nephropathy. Iptacopan, a Factor B…
Sean Hashmi, MD, a board-certified nephrologist and obesity medicine specialist, for his weekly Friday night live sessions from Los Angeles. In this episode, Dr. Hashmi delves into IgA…
Professor Jonathan Barratt, head of the Renal Research Group within the College of Life Sciences at the University of Leicester, discusses the latest advancements in the treatment of…
This video discusses the management of IgA nephropathy, a common and incurable kidney disease. Treatment aims to control the disease and delay kidney damage progression. Lifestyle changes, such…
Explore IgA nephropathy, a rare autoimmune kidney disease where the IgA protein builds up in the kidneys. Normally, IgA helps protect against infections, but in this condition, it…
Dr. Richard Lafayette, founder and director of the Glomerular Disease Center at Stanford University Medical Center, discusses the prevalence and impact of IgA nephropathy, the most common primary…
Obi Umeh, MD, MSc, VP, Franchise Global Program Leader at Takeda, discusses interim results from a study investigating mezagitamab for the treatment of patients with IgA nephropathy. This…
